It is indicated for the treatment of the following infections:

• Acute bacterial exacerbation of chronic bronchitis
• Acute community-acquired pneumonia
• Pharyngitis or tonsillitis
• Skin and soft tissue infections
• Urinary tract infections
• Uncomplicated gonorrhea
• Acute maxillary sinusitis

Cefpodoxime is a third-generation semi-synthetic cephalosporin with activity against a wide range of Gram-positive and Gram-negative bacteria. It remains stable in the presence of beta-lactamase enzymes. Cefpodoxime is particularly effective against methicillin-sensitive Staphylococci, Streptococcus pneumoniae, Haemophilus influenzae, Neisseria species, and Moraxella catarrhalis.

Clavulanic acid is a naturally occurring beta-lactamase inhibitor produced by Streptomyces clavuligerus. It binds to beta-lactamase enzymes and inactivates them, thereby protecting cefpodoxime from degradation and enhancing its antibacterial efficacy.

For adults (Age 12 years and older):

• Acute bacterial exacerbation of chronic bronchitis: 1 tablet 12 hourly for 10 days
• Acute community acquired pneumonia: 1 tablet 12 hourly for 14 days
• Pharyngitis or tonsillitis: ½ tablet 12 hourly for 5 to 10 days
• Skin and soft tissue infections: 2 tablet 12 hourly for 7 to 14 days
• Urinary tract infections: ½ tablet 12 hourly for 7 days
• Uncomplicated gonorrhea: Single dose
• Acute maxillary sinusitis: 1 tablet 12 hourly for 10 days

For children: Children 2 months to 12 years- 10 mg/kg/day in divided dose, every 12 hours.

Concomitant use of cefpodoxime in high doses with antacids or H₂-receptor blockers may reduce the peak plasma concentration of cefpodoxime.

Cefpodoxime is contraindicated in patients with known hypersensitivity to cephalosporin antibiotics.

Cefpodoxime is generally well tolerated. The most common adverse effects are gastrointestinal in nature, including diarrhea, vomiting, and abdominal pain.

The US FDA pregnancy category for cefpodoxime with clavulanic acid is Category B. However, adequate and well-controlled studies in pregnant women are not available. Therefore, it should be used during pregnancy only if clearly needed. Cefpodoxime is excreted in human milk, so caution should be exercised when administered to nursing mothers.

Cefpodoxime should be used cautiously in patients receiving concurrent treatment with diuretics.

Third generation Cephalosporins

Store in a dry place, away from heat and light. Keep out of reach of children.